| Background: Breast cancer is a kind of malignant tumor which clinical treatmenteffect is relatively good,even in the event of a recurrence or metastasis, a largeproportion of patients still get good results through active treatment. Many patientsusually received a variety of drugs and multi-line chemotherapy, such asanthracyclines,taxanes, platinums, xeloda and vinorelbine etc.However, these patientsmay still be faced the progression of the disease once again. For such patients,cisplatin-based joint program can obtain a good effect. But after repeated treatment, thepatient’s general condition is poor, thus limiting the application of cisplatin. At thistime,the choice of treatment drugs is a very thorny problem. Lobaplatin, as a thirdgeneration of platinum anti-cancer chemotherapy drug, has good stability, a widespectrum of anti-tumor, etc. Its activity of anti-cancer is similar with cisplatin, butrenal toxicity and gastrointestinal reaction is lighter, and part of metastatic breastcancer whicih resist to cisplatin and carboplatin also can obtain good effect. In recentyears, LBP has been approved by the State Food and Drug Administration (SFDA) forthe treatment of advanced metastatic breast cancer and good results has beenobtained.S-1as a third-generation oral fluoropyrimidine anti-cancer drug, have a highertolerance compared with capecitabine in patients with metastatic breast cancer and maystill benefit for capecitabine resistant patients. Japan approved S-1for the treatment ofadvanced breast cancer in2005. Lobaplatin and S-1both are effective drugs for breastcancer in recent years, two drugs have different target points and have differentanti-tumor mechanism. Studies have shown that the combination of two drugs canimprove the efficacy and tolerability of advanced metastatic breast cancer.Objective: Evaluate the efficacy of the combination of Lobaplatin and S-1in the treatment of metastatic breast cancer which failed to multi-line chemotherapy andobserve the safety and influencing factors.Method: Retrospective analysis of36patients of breast cancer which were treatedin the department of medical oncology at the First Affiliated Hospital of Dalian MedicalUniversity and The210Hospital of Chinese PLA for03/01/2010to12/01/2012. Allpatients recurrenced after operation and progressed after multi-line chemotherapy, suchas anthracyclines,taxanes, platinums, xeloda and vinorelbine etc.Then they acceptededthe chemotherapy for Lobaplatin and S-1. Lobaplatin30mg/m2(intravenous infusion,d1)and S-140～60mg/time(two times one day,oral,d1-14) every21days. All patientsreceived two or more cycles of chemotherapy. All patients completed164cycles ofchemotherapy and each patient completed4.6cycles of chemotherapy. Evaluation ofresponse and adverse reactions were practiced every2cycles by CT.Results:All patients can evaluate curative effect,0patient got CR,14patients got PR,12patients got SD,10patients got PD.The ORR(%)was38.9%and the DCR(%)was72.2%.Bone marrow suppression is the most common adverse reactions, mainly for leucopeniaand thrombocytopenia. There were5patients got III degree white blood cells reduceand2patients got IV degree white blood cells reduce. There were7patients got IIIdegree platelet reduce and2patients got IV degree platelet reduce.Conclusion:The combination of Lobaplatin and S-1got well recent curative effect in thetreatment of metastatic breast cancer patients who were multi-line chemotherapy failureand poor general condition. The ORR(%)was38.9%,DCR(%)was72.2%and mTTPwas5.0months. This chemotherapy scheme which has high safety and good tolerance,can be considered as one of the choice of multi-line chemotherapy for metastatic breastcancer. |
PDF Full Text Request